Moxetumomab Pasudotox: Clinical Experience in Relapsed/Refractory Hairy Cell Leukemia.

Julie Feurtado, Robert J Kreitman

Journal: Clinical journal of oncology nursing 2020;23(3):E52-E59

PMID: 31099793

Free Full Text on PubMed Central View on PubMed

Abstract

BACKGROUND

Moxetumomab pasudotox is a promising new therapy for the treatment of patients with relapsed/refractory hairy cell leukemia (R/R HCL), but practical guidance relating to its administration is limited.

OBJECTIVES

This article describes clinical guidelines for the administration of moxetumomab pasudotox to patients with R/R HCL and presents related case studies.

METHODS

A limited review of the literature on HCL was undertaken.

FINDINGS

Nursing care of patients prescribed moxetumomab pasudotox includes monitoring clinical and laboratory parameters, managing side effects, being aware of signs of serious side effects, and maintaining patient hydration during administration.

Address: National Cancer Institute at the National Institutes of Health.

DOI: 10.1188/19.CJON.E52-E59

Link outs

Free resources

Full Text Sources:

Subscription / membership required

Full Text Sources:

MeSH Terms: Bacterial Toxins, Clinical Trials, Phase I as Topic, Drug Administration Schedule, Exotoxins, Female, Humans, Infusions, Intravenous, Leukemia, Hairy Cell, Male, Monitoring, Physiologic, Nurse's Role, Patient Selection, Prognosis, Recurrence, Risk Assessment, Survival Analysis, Treatment Outcome